Delcath Systems Stock Is Rocketing Higher: What's Going On?
Portfolio Pulse from Adam Eckert
Delcath Systems Inc's shares are surging after the FDA approved its HEPZATO KIT for the treatment of a rare form of metastatic cancer. Following the approval, Canaccord Genuity analyst Arlinda Lee maintained a Buy rating for Delcath and raised the price target from $14 to $18.
August 15, 2023 | 2:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Delcath Systems Inc's stock is likely to rise in the short term due to the FDA approval of its HEPZATO KIT and the raised price target by Canaccord Genuity.
The FDA approval of Delcath's HEPZATO KIT is a significant positive development for the company. This, coupled with the raised price target by Canaccord Genuity, is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100